Truist Financial Sticks to Its Hold Rating for Gilead Sciences (GILD)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
BofA says Gilead investors ‘can’t be totally dismissive’ of proposed CDC cuts
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
pharmaphorum19h
Mirador’s massive $400m first round, and other financings
The company – led by Mark McKenna ... Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst others. The cash will be used for further clinical development of Enliven ...